Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.6
3.6
Journals
Diagnostics
Special Issues
Prostate Cancer: Challenges in Diagnosis and Management
share announcement

Prostate Cancer: Challenges in Diagnosis and Management

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Medical Imaging and Theranostics".

Deadline for manuscript submissions: closed (31 March 2024) | Viewed by 1083

Special Issue Editors

Dr. Jui-Ming Liu

E-Mail Website
Guest Editor
1. Division of Urology, Department of Surgery, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan
2. Department of Obstetrics and Gynecology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan
Interests: prostate cancer; surgical urology; androgen deprivation therapy; health data mining; precision medicine
Dr. Cheng-Kuang Yang

E-Mail Website
Guest Editor
Department of Urology, Taichung Veterans General Hospital, Taichung, Taiwan
Interests: prostate cancer; urothelial carcinoma; renal cell carcinoma surgical oncology; robot-assisted laparoscopic surgery
Special Issues, Collections and Topics in MDPI journals
Dr. Ren-Jun Hsu

E-Mail Website
Guest Editor
1. Cancer Research Center, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan
2. College of medicine, Tzu Chi University, Hualien, Taiwan
Interests: immunotherapy; cell therapy; clinical trials; radiobiology; molecular oncology

Special Issue Information

Dear Colleagues,

This Special Issue, entitled "Prostate Cancer: Challenges in Diagnosis and Management", seeks to address the pressing concerns and hurdles encountered in the current diagnostic procedures and management strategies for prostate cancer. This Issue aims to be a beacon of knowledge, shedding light on the intricacies of prostate cancer, which is one of the most common cancers affecting men globally.

The focus is on the advancements in diagnostic tools, including imaging techniques and biomarker discovery, that could potentially revolutionize early detection and intervention strategies. This Special Issue encourages submissions that delve deeper into diagnosing prostate cancer and explore the potential of personalized medicine to improve diagnostic outcomes and novel management approaches.

We intend to foster a multidisciplinary dialogue by welcoming contributions from various fields including molecular oncology and clinical trials. The hope is that by fostering collaboration and knowledge exchange, this Special Issue can accelerate the pace of research and development in the fight against prostate cancer, ultimately paving the way for more effective and targeted interventions.

Dr. Jui-Ming Liu
Dr. Cheng-Kuang Yang
Dr. Ren-Jun Hsu
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • prostate cancer
  • surgical urology
  • endourology
  • robot-assisted surgery
  • immunotherapy
  • cell therapy
  • hormone therapy
  • radiation therapy
  • precision medicine
  • diagnostic tools

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

12 pages, 903 KiB  
Article
Comparative Study of Eclipse and RayStation Multi-Criteria Optimization-Based Prostate Radiotherapy Treatment Planning Quality
by John Y. K. Wong, Vincent W. S. Leung, Rico H. M. Hung and Curtise K. C. Ng
Diagnostics 2024, 14(5), 465; https://doi.org/10.3390/diagnostics14050465 - 20 Feb 2024
Viewed by 869
Abstract
Multi-criteria optimization (MCO) function has been available on commercial radiotherapy (RT) treatment planning systems to improve plan quality; however, no study has compared Eclipse and RayStation MCO functions for prostate RT planning. The purpose of this study was to compare prostate RT MCO [...] Read more.
Multi-criteria optimization (MCO) function has been available on commercial radiotherapy (RT) treatment planning systems to improve plan quality; however, no study has compared Eclipse and RayStation MCO functions for prostate RT planning. The purpose of this study was to compare prostate RT MCO plan qualities in terms of discrepancies between Pareto optimal and final deliverable plans, and dosimetric impact of final deliverable plans. In total, 25 computed tomography datasets of prostate cancer patients were used for Eclipse (version 16.1) and RayStation (version 12A) MCO-based plannings with doses received by 98% of planning target volume having 76 Gy prescription (PTV76D98%) and 50% of rectum (rectum D50%) selected as trade-off criteria. Pareto optimal and final deliverable plan discrepancies were determined based on PTV76D98% and rectum D50% percentage differences. Their final deliverable plans were compared in terms of doses received by PTV76 and other structures including rectum, and PTV76 homogeneity index (HI) and conformity index (CI), using a t-test. Both systems showed discrepancies between Pareto optimal and final deliverable plans (Eclipse: −0.89% (PTV76D98%) and −2.49% (Rectum D50%); RayStation: 3.56% (PTV76D98%) and −1.96% (Rectum D50%)). Statistically significantly different average values of PTV76D98%,HI and CI, and mean dose received by rectum (Eclipse: 76.07 Gy, 0.06, 1.05 and 39.36 Gy; RayStation: 70.43 Gy, 0.11, 0.87 and 51.65 Gy) are noted, respectively (p < 0.001). Eclipse MCO-based prostate RT plan quality appears better than that of RayStation. Full article
(This article belongs to the Special Issue Prostate Cancer: Challenges in Diagnosis and Management)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop